KR101084412B1 - 코팅된 제약 용기 내 안정화된 액상 단백질 제제 - Google Patents

코팅된 제약 용기 내 안정화된 액상 단백질 제제 Download PDF

Info

Publication number
KR101084412B1
KR101084412B1 KR20057021160A KR20057021160A KR101084412B1 KR 101084412 B1 KR101084412 B1 KR 101084412B1 KR 20057021160 A KR20057021160 A KR 20057021160A KR 20057021160 A KR20057021160 A KR 20057021160A KR 101084412 B1 KR101084412 B1 KR 101084412B1
Authority
KR
South Korea
Prior art keywords
container
pharmaceutical composition
formulation
comp
closure means
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR20057021160A
Other languages
English (en)
Korean (ko)
Other versions
KR20060009913A (ko
Inventor
파브리지오 사마리타니
알레산드라 델 리오
Original Assignee
아레스 트레이딩 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33442722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101084412(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아레스 트레이딩 에스.에이. filed Critical 아레스 트레이딩 에스.에이.
Publication of KR20060009913A publication Critical patent/KR20060009913A/ko
Application granted granted Critical
Publication of KR101084412B1 publication Critical patent/KR101084412B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/002—Closures to be pierced by an extracting-device for the contents and fixed on the container by separate retaining means
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/005—Closures provided with linings or internal coatings so as to avoid contact of the closure with the contents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
KR20057021160A 2003-05-13 2004-05-12 코팅된 제약 용기 내 안정화된 액상 단백질 제제 Expired - Fee Related KR101084412B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03010671.0 2003-05-13
EP03010671 2003-05-13
PCT/EP2004/050779 WO2004100979A2 (en) 2003-05-13 2004-05-12 Liquid stabilized protein formulations in coated pharmaceutical containers

Publications (2)

Publication Number Publication Date
KR20060009913A KR20060009913A (ko) 2006-02-01
KR101084412B1 true KR101084412B1 (ko) 2011-11-21

Family

ID=33442722

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20057021160A Expired - Fee Related KR101084412B1 (ko) 2003-05-13 2004-05-12 코팅된 제약 용기 내 안정화된 액상 단백질 제제

Country Status (22)

Country Link
US (2) USRE43331E1 (cg-RX-API-DMAC7.html)
EP (2) EP2324845A1 (cg-RX-API-DMAC7.html)
JP (2) JP2007502684A (cg-RX-API-DMAC7.html)
KR (1) KR101084412B1 (cg-RX-API-DMAC7.html)
CN (1) CN1809376B (cg-RX-API-DMAC7.html)
AR (1) AR044302A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004237982C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0410679A (cg-RX-API-DMAC7.html)
CA (1) CA2523477A1 (cg-RX-API-DMAC7.html)
CY (1) CY1115233T1 (cg-RX-API-DMAC7.html)
DK (1) DK1633388T3 (cg-RX-API-DMAC7.html)
EA (1) EA008308B1 (cg-RX-API-DMAC7.html)
ES (1) ES2471942T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140267T1 (cg-RX-API-DMAC7.html)
IL (1) IL171912A (cg-RX-API-DMAC7.html)
MX (1) MXPA05012191A (cg-RX-API-DMAC7.html)
NO (1) NO20055774D0 (cg-RX-API-DMAC7.html)
PL (1) PL1633388T3 (cg-RX-API-DMAC7.html)
PT (1) PT1633388E (cg-RX-API-DMAC7.html)
SI (1) SI1633388T1 (cg-RX-API-DMAC7.html)
UA (1) UA91493C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004100979A2 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879320B2 (en) * 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
US7731948B2 (en) * 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
EP1845925B1 (en) 2005-01-12 2016-08-24 Biogen MA Inc. Method for delivering interferon-beta
CA2615731A1 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
US20070253985A1 (en) * 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
KR100785070B1 (ko) 2006-07-11 2007-12-12 삼성전자주식회사 휴대 단말기에서 디지털 저작권 관리 콘텐츠 재생 방법 및장치
AU2008269086B2 (en) 2007-06-25 2014-06-12 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
RS52417B (sr) * 2007-12-20 2013-02-28 Merck Serono S.A. Formulacije peg-interferona-beta
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
CN107095846A (zh) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
FR2966044B1 (fr) * 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
CA2890933C (en) 2012-12-03 2021-06-08 Novobiotic Pharmaceuticals, Llc Novel depsipeptide and uses thereof
BR112015017307A2 (pt) 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
WO2014159554A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
PT3613423T (pt) 2013-07-10 2022-12-07 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e suas utilizações
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
JP6685897B2 (ja) * 2014-03-13 2020-04-22 ステヴァナト グループ インターナショナル エイ.エス. 液体製剤を処理する方法
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US20160185848A1 (en) 2014-07-09 2016-06-30 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using sugars
WO2016144773A1 (en) 2015-03-06 2016-09-15 Abbvie Inc. Arabinosylated glycoproteins
WO2016163764A2 (ko) * 2015-04-07 2016-10-13 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
PT3352766T (pt) 2015-09-24 2022-03-22 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e processos para o seu uso
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and its use
ES2981759T3 (es) 2017-04-04 2024-10-10 Novobiotic Pharmaceuticals Llc Nuevos depsipéptidos y sus usos
US12629445B2 (en) 2020-03-20 2026-05-19 Bard Peripheral Vascular, Inc. Reactive hydrogel forming formulations and related methods, including methods of preparation
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
WO2022146917A1 (en) 2020-12-28 2022-07-07 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028007A1 (en) * 1996-12-24 1998-07-02 Biogen, Inc. Stable liquid interferon formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2622598A (en) 1951-03-08 1952-12-23 Premo Pharmaceutical Lab Inc Drain-clear container for aqueous liquid pharmaceutical preparations
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
JP3332379B2 (ja) 1992-05-06 2002-10-07 マリンクロッド・インコーポレイテッド 次亜塩素酸ナトリウム溶液の安定性保持用容器封鎖物システム
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW249202B (cg-RX-API-DMAC7.html) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
JP4057058B2 (ja) 1995-11-07 2008-03-05 ジェネンテック インコーポレーテッド Ngfの安定化処方
US6142977A (en) 1996-10-18 2000-11-07 Schering Ag Prefilled, sterilized syringe with a new and improved plug
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CN2326243Y (zh) 1997-09-29 1999-06-30 程继勇 覆膜药用瓶塞
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
CN2441750Y (zh) * 2000-06-23 2001-08-08 程继勇 表面覆膜药用橡胶瓶塞
JP2002209975A (ja) * 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
CN1133565C (zh) * 2001-10-18 2004-01-07 郑秀娣 药品瓶塞隔离膜

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028007A1 (en) * 1996-12-24 1998-07-02 Biogen, Inc. Stable liquid interferon formulations

Also Published As

Publication number Publication date
JP2012096063A (ja) 2012-05-24
WO2004100979A3 (en) 2005-05-19
MXPA05012191A (es) 2006-02-08
HRP20140267T1 (hr) 2014-04-25
PL1633388T3 (pl) 2014-08-29
CA2523477A1 (en) 2004-11-25
EP1633388B1 (en) 2014-03-19
CY1115233T1 (el) 2017-01-04
WO2004100979A2 (en) 2004-11-25
IL171912A (en) 2015-02-26
US7540382B2 (en) 2009-06-02
BRPI0410679A (pt) 2006-06-20
EA008308B1 (ru) 2007-04-27
CN1809376A (zh) 2006-07-26
AU2004237982C1 (en) 2018-03-08
NO20055774L (no) 2005-12-06
AR044302A1 (es) 2005-09-07
CN1809376B (zh) 2010-04-28
ES2471942T3 (es) 2014-06-27
EP1633388A2 (en) 2006-03-15
SI1633388T1 (sl) 2014-05-30
US20070092487A1 (en) 2007-04-26
IL171912A0 (en) 2006-04-10
HK1088558A1 (zh) 2006-11-10
DK1633388T3 (da) 2014-04-07
JP2007502684A (ja) 2007-02-15
UA91493C2 (uk) 2010-08-10
USRE43331E1 (en) 2012-05-01
AU2004237982B2 (en) 2010-03-04
EA200501692A1 (ru) 2006-06-30
PT1633388E (pt) 2014-06-25
EP2324845A1 (en) 2011-05-25
KR20060009913A (ko) 2006-02-01
AU2004237982A1 (en) 2004-11-25
NO20055774D0 (no) 2005-12-06

Similar Documents

Publication Publication Date Title
EP1633388B1 (en) Liquid stabilized interferon-beta formulations in coated pharmaceutical containers
US20240238382A1 (en) URI Agonist/Vasodilator
BG65418B1 (bg) Кит за парентерално приложение на стабилни течни интерферонови състави
JP2014208656A (ja) 成長ホルモン製剤
US10632043B2 (en) Premix formulation for parenteral use and packaging thereof
US20170128421A1 (en) Premix formulation for parenteral use and packaging thereof
AU2017225236B2 (en) A lyophilised pharmaceutical formulation and its use
US20170360891A1 (en) Stable, Benzyl Alcohol-free Aqueous Solution Formulations Containing Alpha-type Interferon
EP4732829A1 (en) Glp-1-fc-fgf21 double-target fusion protein composition, and injection and use thereof
AU2022386352B2 (en) Preserved formulations
HK1088558B (en) Liquid stabilized protein formulations in coated pharmaceutical containers
HK40077155A (en) A lyophilised pharmaceutical formulation and its use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20141022

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20151016

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20161019

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20171111

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20171111